Ubs Group Ag Autolus Therapeutics PLC Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Ubs Group Ag holds 156,978 shares of AUTL stock, worth $359,479. This represents 0.0% of its overall portfolio holdings.

Number of Shares

156,978

Previous 135,791 15.6%

Holding current value

$359,479

Previous $472,000 20.55%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.38 - $4.69 $71,612 - $99,367	21,187 Added 15.6%	156,978 $569,000
Q2 2024 Aug 13, 2024	BUY	$3.33 - $5.68 $143,000 - $243,916	42,943 Added 46.25%	135,791 $472,000
Q1 2024 May 13, 2024	BUY	$5.39 - $7.29 $44,160 - $59,726	8,193 Added 9.68%	92,848 $592,000
Q4 2023 Feb 09, 2024	BUY	$2.13 - $6.63 $4,994 - $15,547	2,345 Added 2.85%	84,655 $545,000
Q3 2023 Nov 09, 2023	BUY	$2.32 - $3.36 $28,343 - $41,049	12,217 Added 17.43%	82,310 $191,000
Q2 2023 Aug 11, 2023	BUY	$1.64 - $3.21 $9,390 - $18,380	5,726 Added 8.9%	70,093 $166,000
Q1 2023 May 12, 2023	BUY	$1.75 - $2.25 $82,894 - $106,578	47,368 Added 278.65%	64,367 $118,000
Q4 2022 Feb 08, 2023	SELL	$1.74 - $3.27 $43,110 - $81,017	-24,776 Reduced 59.31%	16,999 $32,000
Q3 2022 Nov 10, 2022	SELL	$2.04 - $3.76 $607 - $1,120	-298 Reduced 0.71%	41,775 $89,000
Q2 2022 Aug 10, 2022	SELL	$2.04 - $4.68 $64,841 - $148,753	-31,785 Reduced 43.04%	42,073 $118,000
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $228,124 - $353,851	64,808 Added 716.11%	73,858 $308,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $7,930 - $10,885	1,555 Added 20.75%	9,050 $47,000
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $45,677 - $63,278	-8,586 Reduced 53.39%	7,495 $49,000
Q2 2021 Aug 13, 2021	SELL	$4.78 - $7.96 $12,585 - $20,958	-2,633 Reduced 14.07%	16,081 $107,000
Q1 2021 May 12, 2021	BUY	$5.49 - $9.36 $72,303 - $123,271	13,170 Added 237.55%	18,714 $107,000
Q4 2020 Feb 11, 2021	BUY	$8.13 - $12.79 $18,577 - $29,225	2,285 Added 70.11%	5,544 $50,000
Q3 2020 Nov 12, 2020	SELL	$11.64 - $16.3 $19,077 - $26,715	-1,639 Reduced 33.46%	3,259 $38,000
Q2 2020 Jul 31, 2020	BUY	$5.38 - $16.14 $8,957 - $26,873	1,665 Added 51.5%	4,898 $79,000
Q4 2019 Feb 14, 2020	SELL	$11.13 - $16.28 $22 - $32	-2 Reduced 0.06%	3,233 $43,000
Q3 2019 Nov 14, 2019	SELL	$9.79 - $16.72 $29 - $50	-3 Reduced 0.09%	3,235 $40,000
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $48,893 - $101,187	3,238 New	3,238 $52,000
Q1 2019 May 14, 2019	SELL	$24.38 - $34.71 $21,551 - $30,683	-884 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$24.21 - $48.01 $19,561 - $38,792	808 Added 1063.16%	884 $29,000
Q3 2018 Nov 14, 2018	SELL	$20.86 - $33.33 $4,505 - $7,199	-216 Reduced 73.97%	76 $2,000
Q2 2018 Aug 14, 2018	BUY	$25.0 - $27.75 $7,300 - $8,103	292 New	292 $8,000

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account